Pruritus News and Research

RSS
Study explains why some drugs work well in ameliorating side effects of chemotherapy

Study explains why some drugs work well in ameliorating side effects of chemotherapy

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Takeda presents vedolizumab phase 3 VISIBLE 1 trial results for treatment of moderately to severely active ulcerative colitis

Takeda presents vedolizumab phase 3 VISIBLE 1 trial results for treatment of moderately to severely active ulcerative colitis

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

NCCN adds COPIKTRA capsules to NCCN Guidelines for follicular lymphoma

NCCN adds COPIKTRA capsules to NCCN Guidelines for follicular lymphoma

Phase 3 ECHELON-2 clinical trial evaluating ADCETRIS plus CHP meets primary endpoint

Phase 3 ECHELON-2 clinical trial evaluating ADCETRIS plus CHP meets primary endpoint

Pfizer announces FDA approval of VIZIMPRO for first-line treatment of EGFR-mutated metastatic NSCLC

Pfizer announces FDA approval of VIZIMPRO for first-line treatment of EGFR-mutated metastatic NSCLC

Research shows enlarged genotype-phenotype correlation for three-base pair deletion in NF1

Research shows enlarged genotype-phenotype correlation for three-base pair deletion in NF1

FDA approves Teva’s AJOVY injection for preventive treatment of migraine in adults

FDA approves Teva’s AJOVY injection for preventive treatment of migraine in adults

Pediatric antibiotic prescriptions lead to nearly 70,000 ER visits in the U.S. each year

Pediatric antibiotic prescriptions lead to nearly 70,000 ER visits in the U.S. each year

CNDA approves KEYTRUDA for treatment of advanced melanoma

CNDA approves KEYTRUDA for treatment of advanced melanoma

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Opdivo plus low-dose Yervoy shows promising results in treating renal cell carcinoma patients

Opdivo plus low-dose Yervoy shows promising results in treating renal cell carcinoma patients

FDA approves novel enzyme therapy for adults with rare and serious genetic disease

FDA approves novel enzyme therapy for adults with rare and serious genetic disease

Celgene to share new and updated data around novel hematological therapies

Celgene to share new and updated data around novel hematological therapies

New results reinforce COPAXONE 40 mg/mL as safe and effective for RMS patients

New results reinforce COPAXONE 40 mg/mL as safe and effective for RMS patients

New data from VOYAGE 2 trial shows promising results for Janssen’s guselkumab treatment

New data from VOYAGE 2 trial shows promising results for Janssen’s guselkumab treatment

Novartis announces FDA approval of its first and only CML therapy with TFR data in product label

Novartis announces FDA approval of its first and only CML therapy with TFR data in product label